Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5

@article{Gasparian2009GenerationON,
  title={Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5},
  author={Marine E. Gasparian and Boris V Chernyak and Dmitry A. Dolgikh and Anne V. Yagolovich and Ekaterina N Popova and Anna M. Sycheva and Sergey Moshkovskii and Mikhail P. Kirpichnikov},
  journal={Apoptosis},
  year={2009},
  volume={14},
  pages={778-787}
}
TRAIL (tumor necrosis factor (TNF) related apoptosis-inducing ligand) has been introduced as an extrinsic pathway inducer of apoptosis that does not have the toxicities of Fas and TNF. However, the therapeutic potential of TRAIL is limited because of many primary tumor cells are resistant to TRAIL. Despite intensive investigations, little is known in regards to the mechanisms underlying TRAIL selectivity and efficiency. A major reason likely lies in the complexity of the interaction of TRAIL… CONTINUE READING
11 Citations
34 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 34 references

Receptor-selective mutants of Apo2L/ TRAIL reveal a greater contribution of DR5 than DR4 to apoptosis signaling

  • FR Kelley, K Totpal, SH Lindstrom, M Mathieu, K Billeci, L de Forge
  • J Biol Chem 280:2205–2212
  • 2005
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…